In this episode, Dennis Walker and Ash Ritter dive into the world of the infamous Amanita Muscaria mushroom, as well as learn about the wild desert apothecary of fungi and herbs that she researches and teaches about.
Similar Posts
Spotlight Roundup-Another Psychedelic Company Lists On The Nasdaq
June 9, 2021- This week’s Psychedelic Business News top stories…
Andrew Yang Supports LEGALIZING PSILOCYBIN in New York (But Can He Do It?)
Hello psychedelic investors! Today’s episode is a bit different yet still relevant to all of us invested in the psychedelic industry!
To summarize,
Andrew Yang comes out Hard against the war on drugs and for legalizing psilocybin. He says “The war on drugs has been a war on people”.
Specifically, Andrew Yang calls out the criminalization of opioid use, saying big pharma has gotten these people addicted while “generating billions of dollars of blood money”, and then we throw people in jail for the pharma industries failures.
This is, in Yang’s eyes, not a criminal problem, but a public health problem.
If people are addicted to something, don’t throw them in jail, get them the help that they need to treat an illness that in many cases was caused by billionaire pharma companies.
How will Andrew Yang create a de facto decriminalization?
He would instruct the DA not to prosecute for possession charges.
Its that simple.
Finally he talks about how he is for the legalization of psilocybin and open to legalize other substances.
Yang is calling for decriminalizing the use of all drugs, AND to legalize psilocybin..
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
For any collaborations, you can reach us on our email
email: thepsychedelicinvestor@gmail.com
If you are thinking of joining Benzinga Pro, why not use our link, and we will both get a discount!
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#AndrewYang #AndrewYangMayor #AndrewYangDebate
MindMed Releases LSD for Anxiety Data ! (MNMD, MMED)
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Join our Newsletter (scroll to the bottom of the page and sign up):
https://psychedelicspotlight.com/
Follow us on Twitter:
The Psychedelic Investor: @PSYCBiz
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@psycbiz
@psycspotlight
❗❗❗ The Psychedelic Investor will be changing its name to PSYC Business very soon.
Stay tuned for more updates!
In today’s episode, we discuss MindMed (Nasdaq: MNMD, NEO:MMED) and its Phase 2 LSD Trial Treating Anxiety Results.
MindMed (Nasdaq: MNMD, NEO:MMED) finally gave the world a glimpse into its LSD-as-medicine project today.
Speaking at the highly anticipated PSYCH Symposium in London, researchers Prof. Matthias Liechti and Dr. Friederike Holze presented topline data of a Phase 2, double-blind, placebo-controlled study, attempting to treat anxiety disorders with LSD in 46 patients. Patients received 200 µg (micrograms) of LSD, which is considered a large dose.
The results were very positive, though perhaps not paradigm shifting — yet.
The primary endpoint of the study was the reduction in anxiety levels 16 weeks after the administration of LSD. They measured this using a questionnaire called the State Trait Anxiety Inventory, better known by its acronym STAI. In short, a person can have a score between 0 and 63, with the higher the score, the worse the anxiety.
The study found that 65% of patients saw their anxiety levels drop by at least 30% from where they were before treatment, 16 weeks after dosing. This compared to only 9% of patients in the placebo arm reaching that 30% level. The average reduction in the STAI was 16.2 points.
Importantly, there was only one serious adverse event in the trial, which consisted of “acute transient anxiety and delusions” during the LSD experience. It does not appear that this patient had any troubles once the effects wore off. In sum, the administration of large doses of LSD appears to be very safe, even if one person did have a particularly bad experience during the dosing.
Furthermore, when looking at secondary variables that measure depression, anxiety and other major psychiatric symptoms (Hamilton Depression Scale, Beck Depression Index, Symptom-Check-List-90-R) the results “showed similarly rapid and sustained responses consistent with a lasting treatment effect.”
In sum, according to MindMed, the topline data demonstrates “the significant, rapid, durable, and beneficial effects of LSD and potential to safely mitigate symptoms of anxiety and depression.”
Interested in reading the article? Click here: 👇
MindMed’s Phase 2 LSD Trial Treating Anxiety Was a Success
https://psychedelicspotlight.com/mindmed-lsd-anxiety-phase-2-trial-psych-symposium/
#MindMed #Anxiety #MNMD
Psychedelic Spotlight Interview with Douglas K. Gordon
Psychedelic Spotlight Interview with Douglas K. Gordon In this episode…
Atai Life Sciences IPOing TOMORROW ( Is Atai a BUY?)
ATAI IPOS TOMORROW! It’s finally happening! This Friday, on June 18th, 2021, the company I’ve been talking about for a while now, Atai Life Sciences, is set to IPO on the NASDAQ stock exchange, under ticker symbol “atai”.
This will automatically make Atai a runner for the title of the most advanced public psychedelic medicines company on the market.
So in this episode, we’ll discuss several things:
1. The details of the IPO
2. We’ll take a look at their financials
3. Look at Atai Life Sciences’ investment thesis
4. What I will be doing
Enjoy the episode!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Website: https://thepsychedelicinvestor.com/
editing: @themyaholy
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
https://www.atai.life/
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#Atai #AtaiLifeSciences #AtaiIPO
MindMed Nasdaq Uplisting STOCK PREDICTIONS // How Far will MindMed Go? [MMED/ MMEDF]
Here are my MindMed NASDAQ uplisting STOCK PREDICTIONS! MindMed announced on 23rd of April that the MMEDF stock will uplist on NASDAQ on April 27th under ticker MNMD. for MMED : NEO owners, the stock ticker will remain the same, adjusted to US ER.
On the day the news was announced, MMED and MMEDF gained 65.26% , rising from $2.13 to a day high of to $3.57 Though in the last few days the price had fallen, it was still up by 30.86% over the past 2 weeks. MindMed volume increased on the last day, in total, 14 million more shares were traded that the day before. This giant bump brought a lot of MindMed stock speculation which is why we’re making this episode.
Where does MindMed go from here on? MMED / MNMD is still just at the beginning of their long-term growth trajectory so we could only do our due diligence while speculating.
Some speculate that some investors might feel inclined to take profits, which is absolutely understandable. But will they take profits right away or wait for the MNMD price to go ballistic or take profits right away? What will happen to the MindMed stock when/if the do?
Others speculate that the uplisting event might create a FOMO movement which could more than 3X the stock’s price which could create a larger FOMO wave and bring MindMed’s stock price to a similar level to Compass Pathways who’s market cap is very close to MindMed’s.
On this channel, we have been repeatedly saying that investing in the psychedelic industry and specifically in Mindmed should be a long-term play and that the potential returns could be a lot higher in a few years, when/if MindMed shows proof that their medicines work and gets FDA approval. So….
In this segment, we’ll discuss FOUR possible cases:
Timestamps:
0:00 – Intro
4:17 – Worst Case
7:48 – Probable Case
9:57 – #WINNING CASE
11:58 – APES TOGETHER STRONG CASE
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedNasdaq #MindMedstock